focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCATCo Regulatory News (CAT)

Share Price Information for CATCo (CAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.00
Bid: 13.00
Ask: 35.00
Change: 0.00 (0.00%)
Spread: 22.00 (169.231%)
Open: 24.00
High: 24.00
Low: 24.00
Prev. Close: 24.00
CAT Live PriceLast checked at -
CATCo Reinsurance Opportunities is an Investment Trust

To provide investors with significant capital returns and long-term distributions by making investments linked to catastrophe reinsurance risks via a variety of insurance-based investments.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

27 Sep 2018 16:05

RNS Number : 2241C
CATCo Reinsurance Opps Fund Ltd
27 September 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

CATCO Reinsurance Opportunities Fund Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligation

Name

Aggregate of Standard Life Aberdeen plc affiliated investment management entities with delegated voting rights on behalf of multiple managed portfolios

City and country of registered office (if applicable)

Edinburgh, Scotland

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

26/09/2018

6. Date on which issuer notified (DD/MM/YYYY):

27/09/2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

10.33

0.00

10.33

937,034,293

Position of previous notification (if

applicable)

9.83

0.00

9.83

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

BMG1961Q2095

N/A

96,821,065

N/A

10.33

SUBTOTAL 8. A

96,821,065

10.33

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

Exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Standard Life Aberdeen plc

Aberdeen Asset Management PLC

Aberdeen Asset Managers Limited

6.91

0.00

6.91

Standard Life Aberdeen plc

Aberdeen Asset Management PLC

Aberdeen Asset Investment Group Limited

Aberdeen Asset Investments Limited

Standard Life Aberdeen plc

Standard Life Investments (Holdings) Limited

Standard Life Investments Limited

Standard Life Aberdeen plc

Aberdeen Asset Management PLC

Aberdeen Standard Investments (Asia) Limited

Standard Life Aberdeen plc

Standard Life Investments (Holdings) Limited

Standard Life Wealth Limited

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

 

In reference to section 9, the shares detailed are managed by the named discretionary investment management entity within multiple portfolios on behalf of underlying clients, based on investment management agreements whereby the client has delegated the exercise of the voting power to the referenced investment manager.

 

 

Place of completion

Edinburgh, United Kingdom

Date of completion

27/09/2018

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUBRVRWOAKUAR
Date   Source Headline
24th May 20064:36 pmRNSRule 8.3- Cambrdige Antibody
24th May 20064:24 pmRNSEPT Disclosure
24th May 20063:55 pmRNSRule 8.3- Cambridge Antibody
24th May 20063:35 pmRNSHolding(s) in Company
24th May 20063:20 pmRNSHolding(s) in Company
24th May 20061:40 pmRNSHolding(s) in Company
24th May 200612:16 pmRNSEPT Disclosure
24th May 200611:46 amRNSEPT Disclosure
24th May 200610:11 amRNSRule 8.3- Cambridge Antibody
24th May 20067:02 amRNSRule 8.1- Cambridge Antibody
23rd May 20066:07 pmRNSMarket Maker Holding
23rd May 20065:01 pmRNSEPT Disclosure
23rd May 20064:29 pmRNSRule 8.3- Cambridge Antibody
23rd May 20063:35 pmRNSRule 8.3- Cambridge Antibody
23rd May 20063:17 pmRNSRule 8.3- Cambridge Antibody
23rd May 200611:46 amRNSEPT Disclosure
23rd May 200611:46 amRNSRule 8.3- Cambridge Antibody
23rd May 200611:42 amRNSEPT Disclosure
23rd May 20067:01 amRNSAstraZeneca Offer for CAT
22nd May 20062:40 pmRNSRule 8.3- Cambridge Antibody
22nd May 20062:37 pmRNSRule 8.3- Cambridge Antibody
22nd May 200612:31 pmRNSEPT Disclosure
22nd May 200611:52 amRNSEPT Disclosure
22nd May 200611:41 amRNSEPT Disclosure
22nd May 20067:01 amRNSInterim Results
19th May 20065:41 pmRNSRule 8.3- Cambridge Antibody
19th May 20064:46 pmRNSEPT Disclosure
19th May 200612:49 pmRNSEPT Disclosure
19th May 200612:16 pmRNSEPT Disclosure
18th May 20065:08 pmRNSEPT Disclosure - Amendment
18th May 20065:05 pmRNSHolding(s) in Company
18th May 20064:28 pmRNSHolding(s) in Company
18th May 20064:27 pmRNSHolding(s) in Company
18th May 20064:25 pmRNSHolding(s) in Company
18th May 20064:00 pmRNSEPT Disclosure
18th May 20063:03 pmRNSRule 8.3- Cambridge Antibody
18th May 200611:44 amRNSEPT Disclosure
18th May 200611:21 amRNSNotice of Results
18th May 200611:08 amRNSEPT Disclosure
18th May 200610:54 amRNSHolding(s) in Company
18th May 20067:00 amRNSMarket Maker Holding
17th May 20063:46 pmRNSRule 8.3- Cambridge Antibody
17th May 20062:55 pmRNSEPT Disclosure - Amendment
17th May 200612:31 pmRNSEPT Disclosure
17th May 200612:28 pmRNSEPT Disclosure
17th May 200611:20 amRNSEPT Disclosure
17th May 200611:00 amRNSMerger Update
17th May 200610:31 amRNSRule 8.3- Cambridge Antibody
16th May 200612:41 pmRNSEPT Disclosure
16th May 200612:17 pmRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.